The global phase III FLAURA2 trial further explored osimertinib with chemotherapy in patients with EGFR Ex19del and/or exon 21 L858R mutations who had not received prior systemic therapy for advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.